HEMATOLOGIC MALIGNANCIES
Clinical trials for HEMATOLOGIC MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGIC MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGIC MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat blood cancers?
Disease control OngoingThis early-phase trial tests a new drug called KQB198, alone or with other cancer medicines, in adults with advanced blood cancers that have not responded to prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 13 participants will…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated May 26, 2026 10:47 UTC
-
New antibody therapy shows promise for Tough-to-Treat blood cancer
Disease control OngoingThis study tests a drug called teclistamab in 40 Japanese patients whose multiple myeloma has returned or stopped responding to treatment. The drug is a bispecific antibody that helps the immune system attack cancer cells. The first part checks safety and the right dose, while th…
Matched conditions: HEMATOLOGIC MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Gene therapy patients monitored for 15 years in safety check
Knowledge-focused ENROLLING_BY_INVITATIONThis study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to monitor for long-term side effects, as required by regulators. Participants …
Matched conditions: HEMATOLOGIC MALIGNANCIES
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC